Evaluation of the Health Technology Assessment Process of the Financial Protection System for High-Cost Diagnoses and Treatments in Chile (Ricarte Soto Law)

被引:4
|
作者
Armijo, Nicolas [1 ]
Espinoza, Manuel [2 ]
Zamorano, Paula
Lahoz, Daniela [3 ]
Yanez, Tamara [4 ]
Balmaceda, Carlos [2 ]
机构
[1] Pontificia Univ Catolica Chile, Ctr Invest Clin, Unidad Evaluat Tecnol Sanitarias, Santiago, Chile
[2] Pontificia Univ Catolica Chile, Dept Salud Pilibl, Santiago, Chile
[3] Fdn Arturo Lopez Perez, Dept Invest Canc, Unidad Evaluat Tecnol Sanitarias, Santiago, Chile
[4] Pontificia Univ Catolica Chile, Fac Quim & Farm, Santiago, Chile
关键词
health policy; health technology assessment; high-costs drugs; Ley Ricarte Soto; rare diseases; health benefit plans; ECONOMIC EVALUATIONS; MULTIPLE-MYELOMA; QUALITY; TRANSFERABILITY; BORTEZOMIB; STRENGTH; GRADE;
D O I
10.1016/j.vhri.2022.08.001
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objectives: In Chile, Ricarte Soto Law defines a financial protection system for high-cost health technologies through a process of prioritization and evaluation of health technologies (ETESA). This study aims to evaluate the ETESA process in terms of its technical content and its coherence with the Chilean regulatory framework. Methodology: This is a documentary review of 34 reports prepared by the Ministry of Health. A data extraction matrix was applied to evaluate the elements in content and process. The analysis evaluated technical errors, process inconsistencies, and disagreements in interpreting results.Results: From 98 technologies, 59 were considered favorable, and 25 received coverage. A total of 20 inconsistencies were identified in the evaluation process, and 39 disagreements were documented on interpreting the results and technical errors. In the prioritization stage, we identified controversies in 44 technologies.Conclusion: The ETESA process of the Ricarte Soto Law is generally consistent with the regulations. Nevertheless, weaknesses persist in both technical and procedural terms. It is expected that the regulatory entity can use these results to implement the necessary improvements
引用
收藏
页码:95 / 101
页数:7
相关论文
共 5 条
  • [1] TREATMENT PATTERNS OF RELAPSING-REMITTING MULTIPLE SCLEROSIS WITHIN THE HIGH COST DRUG LAW (RICARTE SOTO LAW) PROGRAM IN CHILE FROM JULY 2017 TO NOVEMBER 2021
    Cofre, F.
    Rozas, M. F.
    Galleguillos, L.
    Rada, A.
    VALUE IN HEALTH, 2022, 25 (07) : S485 - S485
  • [2] IMPACT OF HEALTH TECHNOLOGY ASSESSMENT IN LITIGATION CONCERNING ACCESS TO HIGH-COST DRUGS
    Aleman, Alicia
    Galan, Ana Perez
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2017, 33 (04) : 411 - 414
  • [3] HIGH-COST DRUGS ASSESSMENT: TWO-YEAR EXPERIENCE OF A HEALTH TECHNOLOGY ASSESSMENT UNIT IN A REFERRAL CANCER CENTER
    Quirland, C.
    Lahoz, D.
    Carreno-Leiton, D.
    Sanhueza, C.
    Gonzalez-Browne, C.
    VALUE IN HEALTH, 2021, 24 : S50 - S51
  • [4] Evaluation of the intensive outpatient clinic: study protocol for a prospective study of high-cost, high-need patients in the University of Utah Health system
    Bannon, Brittany L.
    Lucier, Michelle
    Fagerlin, Angela
    Kim, Jaewhan
    Kiraly, Bernadette
    Weir, Peter
    Ozanne, Elissa M.
    BMJ OPEN, 2019, 9 (01):
  • [5] South Australian Medicines Evaluation Panel in review: providing evidence-based guidance on the use of high-cost medicines in the South Australian public health system
    Lambert, Robyn
    Burgess, Naomi
    Hillock, Nadine
    Gailer, Joy
    Hissaria, Pravin
    Merlin, Tracy
    Pearson, Chris
    Reddi, Benjamin
    Ward, Michael
    Hill, Catherine
    AUSTRALIAN HEALTH REVIEW, 2021, 45 (02) : 207 - 213